CONCLUSIONS
Template-guided biopsy potentially produces a higher cancer detection rate and more accurate assessment of grade. Prostatectomy specimens did not have a high rate of pathologically insignificant disease.
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OBJECTIVE
To explore the ability of a novel transrectal ultrasonography (TRUS) device (TargetScan TM , Envisioneering Medical Technologies, St. Louis MO) that creates a three-dimensional map of the prostate and calculates an optimal biopsy scheme, to accurately sample the prostate and define the true extent of disease, as standard TRUS-guided prostate biopsy relies on the operator to distribute the biopsy sites, often resulting in under-and oversampling regions of the gland.
PATIENTS AND METHODS
In a multicentre retrospective chart review evaluating patients who had a TargetScan
INTRODUCTION
Prostate cancer is the most common solid malignancy in men, with an estimated 218 890 new cases and 27 050 deaths in 2007 [1] . Screening with PSA level and a DRE has led to an increase in detection, and decrease in disease-specific mortality [2] . TRUS-guided prostate biopsy has been the standard method for diagnosing prostate carcinoma, but has several potential shortcomings.
False-negative rates remain of concern, with estimates that office-based TRUS-guided biopsy misses ≈ 30% of clinically significant prostate cancer [3] , and a high percentage (23%) of cancers missed are high-grade (Gleason 8 and 9) [4] . In addition, among those in whom prostate cancer is detected, the manner in which the biopsy cores are obtained makes it difficult to precisely characterize the true extent of the tumour. Standard manually guided biopsy sampling might make Gleason scores or needle-core volumes imprecise. As both correlate with outcome after therapy [5] , an accurate assessment of tumour characteristics is critical for counselling patients and guiding therapy.
The primary technique to minimize falsenegative rates of TRUS-guided biopsy has been to take more cores per biopsy session, and include more laterally placed biopsy cores to sample the peripheral zone [6] [7] [8] . While this has decreased the under-sampling of tumours, it has associated morbidity [9,10], which increases as more cores are taken during biopsies [11] . Also there is increasing concern that patients are being diagnosed with clinically insignificant disease [12] .
Given these limitations of contemporary biopsy schemes, there is a motivation to develop an improved instrument or diagnostic method that has a high detection rate for prostate cancer within the 'window of opportunity' for treatment, but minimizes the The TargetScan TM system (Envisioneering Medical Technologies, St. Louis, MO, USA) is a novel TRUS device that allows accurate needle placement within a template. First, a threedimensional map of the prostate is created; then a computer algorithm calculates an optimum biopsy scheme using the measured dimensions of the prostate. The system then uses a fixed template that allows the physician to biopsy the prostate at specific locations. The instrument can be used for 12-core template biopsy or for targeted and saturation biopsy if indicated. The instrument can be used to target the same region of the prostate in the future if needed, which is particularly useful in patients with suspicious histology, such as atypia, on initial biopsy.
The aim of the present study was to describe a multicentre experience with the TargetScan template-guided biopsy system, and to show how improved precision potentially translates into a higher cancer detection rate without leading to increased detection of pathologically insignificant disease.
PATIENTS AND METHODS
In a multicentre retrospective chart review, after obtaining institutional review board approval at all sites, we retrospectively reviewed the clinical and pathological data of 199 consecutive patients at Washington University, Duke University, and University of Michigan who had a prostate biopsy using the TargetScan system between January 2006 and June 2007. We excluded patients who did not have PSA or DRE findings recorded (two), those who had had a previous diagnosis of prostate cancer (13), and those who were enrolled in a prospective evaluation of the device (44); the final study population comprised 140 patients.
The data extracted from charts included the most recent serum PSA level, DRE findings, number of previous biopsies, pathology from biopsies, and, if performed, surgical pathology from the radical prostatectomy (RP). Pathological variables recorded were Gleason score, volume of disease, margin status, invasion of seminal vesicles, lymph node status, extracapsular extension and perineural invasion. Pathological information was collected from surgical pathology reports, and clinical information, including PSA and DRE findings, were collected primarily from a form completed by the treating physician on the day of the procedure. Other clinical information, including patient age and number of previous biopsies, were obtained from all other documents available in patients' medical records.
The TargetScan system is a commercially available TRUS template-guided prostate biopsy instrument approved by the USA Food and Drug Administration. The instrument has the following components: An endorectal ultrasound probe, which once inserted in the rectum remains fixed for the entire procedure; an ultrasound transducer which moves within the probe to provide, within 1-2 min, a scan of the prostate created in 1-mm increments, thus increasing image precision; a PC-based digital hardware and software system for image planning, data storage and retrieval; a novel single use flexible 18 G Nitinol biopsy needle which is inserted into the biopsy guide parallel to the probe, but exits at 45 ° , thus maximally sampling the peripheral zone.
Using the TargetScan is an office-based procedure, performed under local anaesthesia with patients in the dorsal lithotomy position. The probe is inserted transrectally; the ultrasonograms are taken and can be displayed simultaneously in transverse and sagittal planes, and reconstructed in three dimensions. While the instrument has the capacity for targeted biopsy and saturation biopsy, in our experience, a 12-core template biopsy was used. The system plans a 12-core biopsy using the following algorithm: from the sagittal view, three planes that are equally spaced with respect to prostate apex and base are calculated; at each of the three preselected transverse planes, the left and right edges of the prostate are marked and four locations are calculated for each plane (Fig. 1) . The position of the biopsy guide is quantified using depth of insertion (cm from the apex) and rotational variables (degrees from the 12 o'clock position). The precise location from which samples were taken is stored using the two co-ordinates, and is included in a printed report. The entire procedure lasts ≈ 10 min for a 12-core template biopsy.
We determined the overall cancer detection rate in all patients requiring biopsy, and then in various subgroups based on serum PSA level, DRE findings, and the indication for biopsy. We assessed the pathological significance of cancer detected by evaluating surgical pathology reports in patients who had RP. We defined pathological significance as a Gleason score of ≥ 7, extracapsular disease, positive margins, or > 20% tumour volume in the RP specimen.
RESULTS
The study comprised 140 men (median age 64 years, range 46-85); 107 received care at Washington University, 22 at Duke University, and 11 at the University of Michigan. All patients had a DRE and serum PSA testing. The median (range) serum PSA level in all patients was 5.2 (0.4-87.5) ng/mL. Fifty-eight The template biopsy detected prostate cancer in 50 of the 140 patients (35.7%) and 39 of 82 (48%) having their first biopsy. The cancer detection rate in subgroups based on the indication for biopsy is shown in Table 1 , which also shows the percentage of cancerpositive biopsies based on the number of previous biopsies. Table 2 shows the prostate cancer detection rate in groups stratified by PSA level and DRE findings.
In all, 23 of 50 (46%) patients had a RP; the median (range) Gleason sum score was 7 (6-9) and median volume of disease was 10 (1-30)%. Of the 23 patients, nine (39%) had a positive margin, two (9%) had invasion of the seminal vesicle, none had positive lymph nodes, seven (30%) had extracapsular extension and 13 (57%) had perineural invasion. Based on the definition of pathologically significant disease (Gleason score ≥ 7, extracapsular extension, positive margins, or > 20% tumour volume), only three patients (13%) were found to have pathologically insignificant disease. Comparing the Gleason score from the biopsy cores with that from the RP specimen showed concordance in 12 of the 23 patients (52%), over-grading in two (9%), under-grading in eight (35%), and in one patient (4%), insufficient tissue was obtained on biopsy to assign a Gleason score, but the patient was later assigned Gleason 6 disease after RP.
DISCUSSION
Prostate cancer is the most common malignancy in men [1] . Given the need to detect the cancer during the 'window of opportunity' for treatment, but also the concurrent need to minimize the detection of clinically and pathologically insignificant disease, there has been an increasing search for newer techniques to satisfy these demands. In our experience with the TargetScan device, 48% of patients having their first biopsy and 36% of the entire group were positive for prostate cancer. This is higher than has been observed with traditional TRUS-guided 12-core biopsy, at 27-42%. For example, Gore et al. [15] detected cancer in 139 of 375 (37.1%) of all patients undergoing biopsy, and 112 of 264 (42.4%) patients having their first biopsy. Presti et al.
[8] and Guichard et al. [16] , after evaluating patients having their first biopsy, found a cancer detection rate of 44.4% and 38.7%, respectively; in both studies, patients had a 12-core biopsy. Some studies have reported markedly lower cancer detection rates; e.g. Naughton et al. [17] reported a cancer detection rate of only 27% in their entire group of patients having a 12-core biopsy. While the present study implies that the TargetScan improves detection rates, it is difficult to compare cancer detection rates between these studies, given that there are almost certainly differences in the populations studied.
Not surprisingly, when we assessed subgroups with different indications for biopsy (Table 1) , the highest cancer detection rate was in those having a biopsy for both an elevated PSA level and an abnormal DRE, followed by the group biopsied for an elevated PSA level only, then the group biopsied for abnormal DRE findings only, and finally those biopsied because they had a history of pathological atypia on previous biopsy. As shown in Table 2 , when groups were stratified by both PSA and DRE findings, the highest cancer detection rate was in the subgroup with a positive DRE and PSA level of > 10 ng/mL. As shown in Table 2 , as the PSA level increased, the rate of cancer detection increased both in those with a positive and those with a negative DRE. Overall, patients with a positive DRE also had a higher rate of cancer detection than those with a negative DRE.
In the present patients only three of the 23 (13%) who had a RP had pathologically insignificant disease. Using a slightly different definition of insignificant disease, Epstein et al. [18] found that 16% of 157 men who had a RP after conventional biopsy for clinical stage T1c prostate cancer had pathologically insignificant disease. They defined pathological insignificance as a Gleason score of < 7, tumour volume < 0.2 mL and tumour confined to the prostate. In their study, the number of biopsy cores was not standardized, but had a mean and median of five cores per patient. Given that more cores were obtained in the present study (12), more insignificant disease would be expected to be detected, yet we detected a smaller percentage of insignificant disease. This might reflect that the conventional technique over-samples small foci of cancer, i.e. that the same region This device has various potential advantages over traditional TRUS-guided biopsy. As the probe remains fixed during the procedure, it minimizes image distortion due to probe movement against the prostate. Its capacity to map the prostate and to record the exact location of each core has several important potential advantages. For patients undergoing second biopsies, the pattern can be altered to examine under-sampled regions and suspicious locations can be precisely rebiopsied. Last, the instrument can be used for planned template biopsy, targeted biopsy and saturation biopsy.
While the TargetScan system has shown several improvements over traditional TRUSguided biopsy, there are several advances that could further improve its utility for prostate cancer diagnosis in the future. The current biopsy protocol arrays 12 cores geometrically throughout the prostate, without consideration for the non-random distribution of cancer throughout the prostate, or the need for more cores in larger prostates [20] . Alternative algorithms that adjust for the non-random distribution of tumour within the prostate, and alter the number of cores based on gland volume, could improve the diagnostic ability.
There are several limitations to the present study. It was a retrospective chart review and there is no direct comparison between this device and traditional TRUS-guided biopsy. We attempted to minimize the bias of a retrospective study by collecting objective data except for the DRE findings, which were primarily collected from a document completed by the treating physician at the time of biopsy. Our definition of tumour volume was a percentage and not an absolute number. This is again due to the retrospective nature of the analysis. Prostate tumour volumes at our institutions are reported in this manner. However, a 20% tumour volume for a 20 g prostate would correspond to 4 g of cancer, which exceeds a volume of 0.5 mL. We therefore think that the 20% reference point is a conservative estimate of low tumour volume.
In conclusion, traditional TRUS-guided prostate biopsy technique imprecisely locates the biopsy sites and as a result might not accurately describe the size, location and grade of the tumour, all of which are important in determining the optimum treatment for patients diagnosed with prostate cancer. Transrectal template biopsy offers several advantages over the traditional biopsy, including the ability to uniformly distribute biopsies throughout the prostate and record the location from which biopsy cores were taken, allowing re-biopsy of specific locations of interest in the future. We have shown that the precision of a templateguided approach potentially leads to higher cancer detection rates, without increasing the rate of detection of pathologically insignificant disease.
